Drug intelligence / Profile preview

NT-1551

Development stage: Preclinical
Lead developer: Numiera Therapeutics
Modality: Small Molecules

Overview

NT-1551 is an investigational small molecule drug candidate being developed by Numiera Therapeutics for the treatment of oncology indications, including breast cancer and prostate cancer. The drug is currently in preclinical development. It is part of Numiera's pipeline focusing on cancer cell metabolism and targeting metabolic pathways to inhibit tumor growth.

Targets

CPT1B (Carnitine palmitoyltransferase 1B)

Beyond the preview

Go deeper on NT-1551.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT-1551.

Explore the full profile